Assessment of Clinical and Laboratory Limits between Hashitoxicosis and Graves’ Disease


  •  Juliana Delfino dos Reis    
  •  Taciana Carla Maia Feibelmann    
  •  Beatriz Pires Ferreira    
  •  Marcus Aurelho Lima    
  •  Janaíne Machado Tomé    
  •  Flávia Alves Ribeiro    
  •  Beatriz Hallal Jorge Lara    
  •  Maria de Fátima Borges    

Abstract

BACKGROUND: Determine the clinical and laboratory features of Hashitoxicosis (Htx) and set standards that will help perform a differential diagnosis with Graves’Disease (GD).

SUBJECTS & METHODS: we evaluated 45 patients with Htx (Hashi-group) diagnosed between January/1995 and July/2019 with autoimmune hyperthyroidism and cytology compatible with Hashimoto’s Thyroiditis (HT). The control group consisted of 51 patients with GD (Graves-group).

RESULTS: clinical hyperthyroidism, free T4 (FT4), thyroid volume and need for antithyroid drugs were higher in the Graves-Group. Values of anti-thyroid antibodies and TSH were higher in the Hashi-Group. The definitive diagnostic criterion was cytology. Regarding the clinical course, 95% of the Hashi-Group had hyperthyroidism of short duration, while 84.3% of Graves-Group required radioactive iodine (RAI).

CONCLUSION: hyperthyroidism due to HT was milder than that associated with GD. In most citology was able to distinguish HT from GD and predict spontaneous resolution preventing unnecessary RAI.



This work is licensed under a Creative Commons Attribution 4.0 License.